Therapy

Approval Announced To Collaborate on Anti-Cancer Compounds

Published in Cancer Weekly, March 24th, 1997

Pharmacyclics, Inc., Sunnyvale, California, announced that the Decision Network Committee of the U.S. National Cancer Institute (NCI), has voted unanimously to support additional clinical trials for two products developed by Pharmacyclics based on the texaphyrin technology: gadolinium texaphyrin (Gd-Tex) and lutetium texaphyrin (Lu-Tex).

The company and the NCI have been in the process of structuring a Cooperative Research and Development Agreement (CRADA) in which the NCI intends to sponsor multiple clinical trials evaluating Gd-Tex, a radiation sensitizer (also shown to be potentially useful as a chemosensitizer), and Lu-Tex, a photosensitizer, in several types of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry